Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Clinical Trials

First Opinion

Why did it take the CDC so long to reverse course on debunked treatments for chronic fatigue syndrome?

By Julie Rehmeyer and David Tuller

Biotech

Nabriva novel antibiotic meets goals in late-stage bacterial pneumonia study

By Adam Feuerstein

advertisement

Business

Stakes are high as Alnylam awaits results from novel rare disease therapy

By Adam Feuerstein

advertisement

Business

5 things to know about Sage’s must-win drug trials in postpartum depression

By Adam Feuerstein

Pharma

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

By Adam Feuerstein

Biotech

7 things to know about Sage Therapeutics’ pivotal trial of a drug for severe epilepsy

By Adam Feuerstein

Biotech

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

By Adam Feuerstein

advertisement

First Opinion

How do we solve the crisis in cancer communication?

By Lynn O'Connor Vos

advertisement

Where are they now

Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’

By Rebecca Robbins

Gut Check

Do cancer clinical trials exaggerate the real-world benefits of drugs?

By Sharon Begley

Pharmalot

How much longer will Gilead wait before buying its way out of the doldrums?

By Ed Silverman

Health

‘Colontown’ gives cancer patients an edge in finding new treatments

By David Steen Martin

First Opinion

Right-to-try laws could curtail the development of innovative new therapies

By Alison Bateman-House

Business

Novel system to get dying patients an experimental cancer drug raises hopes — and thorny questions

By Karen Weintraub

Pharmalot

What clinical trial results? Now you can see who isn’t sharing their findings

By Ed Silverman

First Opinion

In defense of data sharing, but done in the right way

By Jeffrey M. Drazen and Isaac S. Kohane

In the Lab

Major trial casts doubt on leading device to heal bone fractures

By Charles Piller

First Opinion

Assess institutional review boards by their quality of decisions, not ownership

By Stephen Rosenfeld and Jim Gearhart

Pharmalot

Pharmalot, Pharmalittle: Drug makers are making huge bets on some cancer meds

By Ed Silverman

In the Lab

Amid crisis, Ebola drug narrowly missed threshold to prove effectiveness

By Andrew Joseph

In the Lab

Should researchers study bunk science? Among respected scientists, a debate ensues

By Helen Branswell

Pharmalot

Pharmalot, Pharmalittle: Alnylam stock plunges after key clinical trial is ended

By Ed Silverman

Health

For cancer patients, newest treatments force the ultimate decision, with no room for error

By Bob Tedeschi

In the Lab

Novel study of pancreatic cancer aims to give patients more treatment options

By Sharon Begley

Pharmalot

European regulators appeal rulings that prevent release of drug data

By Ed Silverman

First Opinion

Bad science misled millions with chronic fatigue syndrome. Here’s how we fought back

By Julie Rehmeyer

Health

For two brothers with Duchenne, an FDA drug approval brings joy and relief

By Jeffery DelViscio

Politics

New federal rules target woeful public reporting of clinical trial results

By Charles Piller

Exclusive

As Parkinson’s patients wait, Fox Foundation and scientist feud over drug trial

By Charles Piller

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Leave this field empty if you're human:

Sign up for our morning rounds newsletter

Leave this field empty if you're human:

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
STAT Wunderkinds
Awards for STAT
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X